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Abstract 
Lysine-specific demethylase 1 (LSD1) targets mono- or di-methylated histone H3K4 and H3K9 as well as non-histone 
substrates and functions in the regulation of gene expression as a transcriptional repressor or activator. This enzyme 
plays a pivotal role in various physiological processes, including development, differentiation, inflammation, thermo-
genesis, neuronal and cerebral physiology, and the maintenance of stemness in stem cells. LSD1 also participates in 
pathological processes, including cancer as the most representative disease. It promotes oncogenesis by facilitating 
the survival of cancer cells and by generating a pro-cancer microenvironment. In this review, we discuss the role of 
LSD1 in several aspects of cancer, such as hypoxia, epithelial-to-mesenchymal transition, stemness versus differentia-
tion of cancer stem cells, as well as anti-tumor immunity. Additionally, the current understanding of the involvement 
of LSD1 in various other pathological processes is discussed.
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Introduction
Post-translational modifications of histone tails with 
various protein and non-protein tags are well-known 
mechanisms regulating chromatin structure and gene 
expression [1, 2]. These histone modifications are revers-
ible and coordinated by the interplay of special “writer” 
and “eraser” enzymes. Lysine methylation of the histone 
tail was considered an irreversible process until lysine-
specific demethylase 1 (LSD1, also known as KDM1A) 
was identified along with its histone demethylase activ-
ity against H3 lysine 4 (H3K4) [3]. LSD1 specifically dem-
ethylates mono- and di-methylated H3K4 through flavin 
adenine dinucleotide (FAD)-dependent amine oxidase 
activity, repressing gene expression by removing active 
histone marks (H3K4me2) from gene promoter regions 
[3] (Table  1). The repressive effect of LSD1 on nucleo-
somal substrates requires its association with other pro-
teins, most notably the corepressor of REST (CoREST) 
protein [4, 5]. Structural studies revealed bivalent inter-
actions between LSD1-CoREST and nucleosomes, during 
which LSD1 recognizes the H3 tail, while CoREST inter-
acts with DNA [6]. In addition to CoREST, LSD1 was 
found in protein complexes with CtBP [7] and NuRD [8]. 
Further, various transcription factors have been reported 
to recruit LSD1 to gene promoters as well as enhancers, 
leading to H3K4 demethylation [9].
In contrast to its repressive role at H3K4, LSD1 func-
tions as a transcriptional coactivator when bound to the 
androgen receptor (AR) via demethylation of repres-
sive histone marks at H3K9, resulting in the derepres-
sion of AR target genes [10]. In addition, a recent study 
revealed the LSD1-mediated demethylation of FOXA1, 
a crucial cofactor for AR chromatin accession. LSD1 
stabilized FOXA1, resulting in the expression of AR tar-
get genes and tumor growth [11]. Thus, LSD1 appears 
to increase AR-mediated transcription by regulating 
chromatin status through the demethylation of H3K9 as 
well as non-histone cofactors. As in the case of FOXA1, 
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LSD1 demethylation targets include non-histone tran-
scriptional regulatory proteins, such as transcription fac-
tors and cofactors. The outcomes of non-histone protein 
methylation vary depending on the target and context, 
but one important consequence is the regulation of pro-
tein stability [12, 13]. Many studies have reported that 
SET7/9-mediated monomethylation of non-histone pro-
teins, including DNMT1, HIF-1α, p65, AGO2, SOX2, and 
FOXA1, induces their ubiquitin-dependent proteasomal 
degradation, while LSD1, by reversing this modification, 
stabilizes substrate proteins against degradation [8, 11, 
14–17]. Lastly, neuron-specific alternative splicing forms 
of LSD1 have been identified with distinct target specific-
ity from that of the original form [18, 19]. The neuronal 
isoform of LSD1 demethylates H3K9me2 in collaboration 
with supervillain, does not exhibit H3K4me2 demethyla-
tion activity, and is involved in neuronal differentiation 
[18]. In addition, this isoform exhibits altered intrinsic 
substrate specificity against H4K20 methylation, a newly 
identified histone substrate, and promotes the transcrip-
tion of genes involved in learning and memory [19].
LSD1 plays pivotal roles in various physiological and 
pathological processes via its demethylase activity against 
both histone and non-histone targets. In this review, we 
discuss the current understanding of LSD1’s involve-
ment in different pathological processes. We focus on 
the molecular mechanisms through which LSD1 con-
tributes to the maintenance of homeostasis and disease 
progression.
LSD1 in cancer
LSD1 is involved in various stages of cancer, includ-
ing development, progression, metastasis, and recur-
rence after therapy. Although overexpression of LSD1 
has been reported in various cancer types and correlated 
with poor overall survival in patients [20–24], LSD1 
does not appear to be a potent oncogene. Instead, LSD1 
supports cancer progression by regulating gene expres-
sion in cancer cells in favor of adaptation to the tumor 
microenvironment. Further, LSD1 is considered a drug 
target in cancer, and numerous LSD1 inhibitors have 
been developed, some of which are currently undergoing 
clinical trials for the treatment of hematological cancers 
as well as lung cancer and other solid tumors [25]. LSD1 
inhibitors are not within the scope of this work and have 
been thoroughly discussed in other reviews [25, 26]. We 
focus on several aspects of cancer wherein LSD1 plays a 
disease-promoting role, such as hypoxia, the epithelial-
to-mesenchymal transition (EMT), cancer stemness and 
differentiation, as well as antitumor immunity.
Regulation of hypoxia by LSD1
Eukaryotic cells including cancer cells have an elaborate 
system for adaptation to low oxygen levels (hypoxia) in 
their microenvironment [27]. Hypoxia induces the tran-
scriptional activation of various genes via the stabiliza-
tion of hypoxia-inducible factor (HIF)-1α [27, 28]. In the 
normal physiological oxygen state (normoxia), a series 
of enzymatic reactions initiated by oxygen-sensing pro-
lyl-hydroxylases (PHDs) maintain HIF-1α at low levels. 
PHD enzymes hydroxylate HIF-1α at its proline residues, 
which serves as a signal for its ubiquitylation by the von 
Hippel-Lindau (VHL)-containing E3 ubiquitin ligase 
complex [29] and subsequent proteasomal degradation. 
Under hypoxic conditions, the lack of oxygen inhibits 
PHD function, leading to HIF-1α stabilization, nuclear 
localization, and transcriptional activation. In addition to 
the oxygen-dependent regulation of HIF-1α stability, oxy-
gen-independent mechanisms, such as the CHIP-HSP70 
or RACK1-HSP90 pathways, are known to degrade 
HIF-1α [30, 31]. Furthermore, various post-translational 
modifications, including acetylation, methylation, and 
SUMOylation, are critical for the regulation of HIF-1α 
stability and function [32, 33].
Table 1 Targets of LSD1 and their effect on gene expression
*  neuron-specific isoform of LSD1
Listed are the target substrates of LSD1 and the cellular functions and effects of gene expression
Targets Residue Functions Effect References
Histone H3 K4me2 Repression with CoREST, CtBP and NuRD Gene repression [6–8]
Histone H3 K9me2 Derepression of AR target genes with FOXA1 Gene activation [10, 11]
Histone H4 K20me1 Regulation of memory formation (LSD1n*) Gene activation [19]
DNMT1 K1096 Maintenance of global DNA methylation through stabilization of DNMT1 Gene activation [8]
FOXA1 K270 Derepression of AR target genes through stabilization of FOXA1 Gene activation [11]
HIF-1α K32 Regulation of tumor angiogenesis through stabilization of HIF-1α Gene activation [14]
p65 K314/315 Regulation of inflammatory response through stabilization of p65 Gene activation [15]
AGO2 K726 Inhibition of anti-tumor immunity through stabilization of AGO2 Gene repression [16]
SOX2 K42/117 Maintenance of pluripotency through stabilization of SOX2 Gene activation [17]
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The role of LSD1 as a positive factor in the hypoxic reg-
ulation of HIF-1α stability and transcriptional activity via 
demethylation of HIF-1α and HIF-1α-interacting protein 
RACK1 has been well studied [14, 34–36]. Monometh-
ylation of the HIF-1α Lys32 residue by SET7/9 mediates 
HIF-1α ubiquitylation and degradation (Fig. 1A) [14, 34]. 
As the E3 ubiquitin ligase that is targeting monomethyl-
ated HIF-1α is not yet known, its identification adds to 
our understanding of HIF-1α stability regulation. Further, 
this E3 ubiquitin ligase may be a promising drug target for 
HIF-1α suppression via PROteolysis Targeting Chimera 
(PROTAC) technology [37, 38], especially in VHL-defec-
tive cancers. Under hypoxic conditions, LSD1 maintains 
HIF-1α stability and hypoxia-responsive gene expression 
by counteracting SET7/9-mediated HIF-1α monomethyl-
ation [14]. A mouse model harboring a lysine-to-alanine 
substitution at HIF-1α Lys32, which prevents its mono-
methylation, exhibited much higher HIF-1α levels, 
upregulated hypoxia-inducible gene expression, as well 
as enhanced tumor growth and angiogenesis [14], sug-
gesting that monomethylation at this lysine residue is a 
critical regulator of HIF-1α function. Lysine monometh-
ylation of HIF-1α also occurs at position 391 and is regu-
lated by the interplay between SET7/9 and LSD1 (Fig. 1A) 
[35]. This site is in close proximity to the oxygen-depend-
ent degradation domain (ODDD) of HIF-1α, and meth-
ylation by SET7/9 enhances VHL-mediated HIF-1α 
ubiquitylation [35]. LSD1 increases HIF-1α stability by 
inhibiting the methylation. In addition, LSD1 prevents 
PHD2-induced hydroxylation and enhances K532 dea-
cetylation (Fig. 1B) [35]. LSD1 increases MTA1 (Metas-
tasis Associated 1, a component of NuRD complex) level 
as well as HDAC activity in NuRD complex, resulting in 
the decrease of Arrest defect 1 (ARD1)-mediated K532 
acetylation. These events stabilize HIF-1α. Another level 
of LSD1-mediated HIF-1α stability regulation is through 
an oxygen-independent mechanism via demethylation of 
RACK1 (Fig.  1B) [36]. RACK1 was identified as a HIF-
1α-interacting protein and was shown to recruit an E3 
ubiquitin ligase independently of oxygen status [30]. 
LSD1 demethylates the Lys271 residue of RACK1, inhib-
iting its interaction with HIF-1α and thus stabilizing the 
latter [36]. Low cofactor FAD levels attenuate LSD1 dem-
ethylase activity during prolonged hypoxia and suppress 
HIF-1α through RACK1-mediated degradation [36]. In 
summary, LSD1 increases HIF-1α stability under hypoxic 
conditions via three mechanisms. First, direct demethyla-
tion of HIF-1α stabilizes it against methylation-mediated 
degradation. Second, LSD1 indirectly inhibits HIF-1α 
hydroxylation-mediated degradation. Third, LSD1 dem-
ethylates RACK1 and inhibits the RACK1-mediated 
degradation of HIF-1α. Thus, LSD1 inhibition is a prom-
ising strategy for preventing cancer cell adaptation to the 
hypoxic microenvironment.
While most studies on the function of LSD1 in hypoxia 
have focused on its regulation of HIF-1α stability, Saka-
moto et al. suggested that histone demethylation by LSD1 
is partially involved in cancer cell metabolic reprogram-
ming [39]. They observed a shift in the metabolic balance 
from glycolytic to mitochondrial respiration upon LSD1 
depletion in hepatocellular carcinoma cells. Reduced glu-
cose uptake and glycolytic activity were correlated with 
the decrease of HIF-1α levels, while elevated mitochon-
drial respiration in parallel to the increase of methyl-
ated H3K4 in the promoter region of respiratory genes. 
In various independent studies, LSD1 was shown to play 
a role in the cellular response to hypoxia [14, 35, 36, 39, 
40]. Since LSD1 levels and activity were associated with 
angiogenesis, tumor growth [35], as well as the metabolic 
shift toward glycolysis [39], LSD1 inhibitors are promis-
ing candidates for suppressing cancer progression in rela-
tion to the hypoxic response.
LSD1 in the epithelial‑to‑mesenchymal transition (EMT)
The EMT is an essential process allowing solid cancer 
cells to gain migratory potential and relocate from their 
original location [41, 42]. The process involves repres-
sion of epithelial marker genes, such as E-cadherin, and 
the activation of mesenchymal marker genes, includ-
ing vimentin. Various transcription factors involved in 























Fig. 1 Regulation of the stability of HIF-1α by LSD1 in hypoxia. A 
Methylation of HIF-1α Lys32 or Lys391 residue by SET7/9 induces 
ubiquitination and degradation of HIF-1α. LSD1 removes the 
corresponding methyl groups and thereby stabilizes HIF-1α. B 
LSD1 prevents PHD2-induced hydroxylation and enhances K532 
deacetylation of HIF-1α, thereby stabilizing HIF-1α. In addition, 
demethylation of RACK1 by LSD1 inhibits the interaction of RACK1 
with HIF-1α, consequently stabilizing HIF-1α
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TWIST, and ZEB families [41, 42]. Among them, SNAIL 
is known to recruit a number of epigenetic regulators in 
order to establish the heterochromatin state in the pro-
moter region of epithelial marker genes [43]. Further, 
LSD1 plays a critical role in the initiation of this epige-
netic repressive state.
LSD1 was initially proposed as a negative regulator of 
EMT and invasion in breast cancer cells, acting through 
the inhibition of TGF-β signaling gene expression via a 
complex formed with NuRD [8]. However, many other 
reports later suggested a role of LSD1 in promoting EMT 
across various types of cancer. The EMT-promoting 
role of LSD1 was first described when it was identified 
as a SNAIL-binding protein [43, 44]. SNAIL interacts 
with LSD1 through the N-terminal SNAG domain and 
recruits LSD1 to target gene promoters (e.g., SNAIL gene 
promoter) via binding to E-box consensus sequences, 
where LSD1 strips H3K4me2 histone marks [43, 44]. 
LSD1 simultaneously recruits the CoREST repressor 
complex to the promoter for transcriptional repression 
[43]. Further, LSD1 contributes to the enhanced stabil-
ity of the SNAIL protein preventing its GSK3β-mediated 
degradation via the ubiquitin–proteasome system [45]. 
Without LSD1 binding, SNAIL failed to repress target 
gene expression [43], highlighting the critical role of the 
former in SNAIL-mediated epithelial gene repression. 
SNAIL family member SLUG (also called SNAIL2) also 
interacts with LSD1 via its SNAG domain [46]. LSD1 
together with SNAIL/SLUG were involved in the repres-
sion of cancer-related genes other than epithelial-specific 
genes depending on the cancer type. Examples included 
BRCA1 (Breast cancer 1; the tumor suppressor) in triple-
negative breast cancer cells [46] and NDRG1 (N-myc 
downstream-regulated gene 1; the metastasis suppres-
sor) in neuroblastoma with the MYCN oncogene ampli-
fication [47]. The contribution of SNAIL-LSD1 to the 
development of acute myeloid leukemia (AML), a hema-
tological malignancy, suggests that the complex is also 
involved in aspects of cancer progression other than the 
EMT [48].
Genome-wide analysis of epigenomic reprogram-
ming during the EMT confirmed the pivotal role of 
LSD1. TGF-β-induced EMT in mouse hepatocytes 
was accompanied by a reduction in heterochromatin 
mark H3K9me2 levels in parallel to an elevation in the 
euchromatin marks H3K36me3 and H3K4me3 [49]. 
Importantly, the major contributor to this reprogram-
ming was found to be LSD1. In addition, the increased 
motility and chemoresistance of TGFβ-treated cells were 
LSD1-dependent [49]. Thus, LSD1 acts a critical epige-
netic EMT regulator via both the repression of epithelial 
gene expression and the activation of mesenchymal gene 
expression. Genome-wide analysis revealed a general 
shift of chromatin structure toward a more open state 
with increased euchromatin histone marks, which was 
not in agreement with the repression of epithelial genes 
during the EMT. One possible scenario is that the repres-
sion of epithelial-specific expression occurred because of 
SNAIL/LSD1-induced local repressive chromatin states 
rather than a broader genomic state of repression.
Post-translational modification of LSD1 contributes 
to its activation during the EMT. Phosphorylation at the 
Ser112 residue is critical for EMT activation [50, 51]. In 
nude mice with LSD1 mutant-expressing MDA-MB-231 
tumors, ectopic overexpression of wild-type LSD1 or 
a phosphorylation-mimicking LSD1-S111D (originally 
reported as S112 referring to mouse LSD1, while S111 is 
the human LSD1 residue) enhanced metastasis, whereas 
overexpression of a phosphorylation-defective S112A 
mutant did not change the metastatic potential of can-
cer cells [50]. The kinase responsible for phosphoryla-
tion at the site was suggested to be chromatin-anchored 
PKC-θ [51], although LSD1-S112 was originally identi-
fied as a target for PKCα in relation to circadian regula-
tion [52] and inflammation [15]. LSD1, together with 
PKC-θ, localized to mesenchymal gene promoters 
and enhanced gene expression, while LSD1 inhibition 
repressed mesenchymal gene induction [51]. In contrast 
to the phosphorylation-mediated activation of LSD1 in 
EMT, acetylation was shown to negatively regulate EMT-
promoting function of LSD1 in epithelial cells, thereby 
attenuating the EMT [53]. Acetyltransferase MOF, which 
is highly expressed in epithelial cells, acetylates LSD1 at 
multiple lysine residues, interfering with its association 
with chromatin and thus compromising the EMT-pro-
moting function of LSD1 [53].
Since LSD1 was identified as a critical player in the 
EMT, various approaches have been employed for block-
ing the EMT via inhibition of either LSD1 activity or the 
SNAIL interaction [54, 55]. Structurally, the N-terminal 
SNAG domain of SNAIL mimics histone H3, allow-
ing for its interaction with LSD1 [56]. Thus, a SNAG 
mimicry peptide blocked the SNAIL-LSD1 interaction 
[55]. In addition, LSD1 demethylase inhibitor tranyl-
cypromine  (Parnate) also suppressed their interaction 
[54, 55]. Further, the treatment of various cancer cell 
lines with these two inhibitory molecules resulted in an 
increased expression of E-cadherin and the suppression 
of motility and invasiveness [54, 55]. LSD1 inhibitors Par-
gyline and GSK-LSD1 were applied to restrict the EMT in 
prostate cancer cells and oral squamous cell carcinoma, 
respectively. These inhibitors activated epithelial genes 
and repressed mesenchymal gene expression, in turn 
suppressing or delaying progression [19, 57]. In sum-
mary, a considerable amount of evidence has confirmed 
the LSD1-mediated promotion of the EMT in various 
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types of cancer. Accordingly, LSD1 inhibitors have been 
successfully applied to suppress the EMT process and 
cancer progression in these preclinical studies.
Maintenance of cancer stemness and regulation 
of differentiation by LSD1
The critical role of LSD1 in the regulation of stemness 
and differentiation was first reported in embryonic stem 
cells (ESCs) of humans and mice [58, 59]. LSD1 repressed 
the expression of several critical developmental genes by 
regulating the methylation status of H3K4 via its enzy-
matic activity [58]. As a result, LSD1 knockdown induced 
the differentiation of human ESCs via the early expres-
sion of mesodermal and endodermal marker genes, in 
parallel to increased levels of H3K4 di- and tri-methyla-
tion [58]. LSD1 depletion in mouse ESCs leads to their 
incomplete differentiation due to the partial silencing of 
ESC genes, as LSD1 was crucial for the decommission-
ing of ESC-specific enhancers during differentiation 
[59]. Many LSD1-regulated genes are its indirect tar-
gets, wherein LSD1 recruitment is mediated by master 
ESC transcription factors, including OCT4, SOX2, and 
NANOG [58, 59]. In addition to its role in ESCs, LSD1 
is involved in the differentiation of adult stem cells in 
various tissues, including myogenic differentiation [60], 
adipogenesis [61], hematopoiesis [62, 63], and epithelial 
differentiation [64]. Taken together, LSD1 is a critical epi-
genetic factor that maintains the self-renewal potential of 
stem cells and regulates their cellular differentiation.
In tumors, a small population of cells containing stem 
cell-like properties (i.e., self-renewal, long-term growth, 
and drug resistance) have been identified and termed 
cancer stem cells (CSCs) [65, 66]. After the characteri-
zation of LSD1 as a pivotal regulator contributing to 
embryonic stem cell stemness and differentiation, various 
groups have explored its role in CSCs. LSD1 inhibition 
via small-molecule compounds selectively suppressed 
the growth of stem-like cancer cells in teratocarcinoma, 
embryonic carcinoma, and testicular seminoma, without 
significant growth inhibition observed in non-pluripo-
tent cancer cells [67]. Since this initial observation, vari-
ous studies have elucidated the function of LSD1 and the 
consequences of LSD1 deletion or pharmacological inhi-
bition in CSCs from a variety of cancer types. Although 
the mechanism of LSD1 function in CSCs varies and has 
not been clearly established, it is related to the regula-
tion of stemness and differentiation, similarly to its role 
in ESCs. Thus, LSD1 inhibition is to be accompanied by 
reduced stemness, cellular differentiation, and/or dimin-
ished drug resistance in CSCs. Pharmacological LSD1 
inhibition in small cell lung carcinoma (SCLC), a noto-
riously drug-resistant lung cancer type, had cytostatic 
effects with a delayed onset of growth both in vitro and 
in xenograft models [68]. LSD1 caused a change in the 
cellular state (i.e., inducing differentiation) via neuroen-
docrine marker gene expression changes, which are a 
molecular feature of SCLCs [68]. Unfortunately, not all 
SCLC cell lines respond to LSD1 inhibition, and the exact 
mechanism through which LSD1 contributes to the CSC 
phenotype has not been elucidated. In squamous cell car-
cinoma (SCC), LSD1 function was associated with the 
stem cell factor SOX2. LSD1 inhibitors selectively sup-
pressed the growth and promoted the differentiation of 
SOX2-positive, but not SOX2-negative, SCCs, in con-
junction with the upregulation of differentiation-associ-
ated genes [69].
In leukemia, LSD1 inhibition promotes cell differen-
tiation. In MLL-AF9-driven leukemia, LSD1 sustained 
the expression of oncogenic genes maintaining stem cell 
potential in concert with the MLL-AF9 oncoprotein. Fur-
ther, knockdown or pharmacological inhibition of LSD1 
attenuated leukemia stem cell potential and induced 
differentiation [70]. Moreover, inhibition successfully 
induced cell fate transition in other types of leukemia. In 
particular, inhibiting LSD1 triggered the differentiation 
of non-acute promyelocytic leukemia (APL)-type AML 
cells, which do not respond to all-trans-retinoic acid 
(ATRA)-mediated differentiation, into ATRA-sensitive 
cells [71]. Interestingly, recent evidence revealed that 
even though LSD1 inhibition was not effective in APL 
cell treatment, it sensitized APL cells to physiological 
doses of retinoic acid so that combination treatment of 
LSD1 inhibitor and retinoic acid extended the survival of 
leukemic mice [72]. However, in this case, the demethyl-
ase activity of LSD1 was not correlated with its retinoic 
acid-mediated sensitizing ability, and LSD1 inhibition 
disrupted the interaction between LSD1 and GFI1 [72]. 
Pharmacological dissociation of LSD1 from the LSD1-
GFI1 complex has been reported as crucial for the 
differentiation of AML cells [73, 74]. In addition, pharma-
cological inhibition of LSD1 in Merkel cell carcinoma, a 
primary neuroendocrine carcinoma of the skin, induced 
cell cycle arrest and cell fate change to the normal Mer-
kel cell phenotype accompanied by the de-repression 
and activation of the neuronal transcription program 
[75]. Thus, LSD1 is a critical player in the maintenance of 
stemness, and LSD1 inhibition has been demonstrated as 
efficient for the treatment of differentiation-prone cancer 
types in pre-clinical models.
LSD1 is likely to regulate the methylation status of lin-
eage- or cancer type-specific gene sets rather than the 
global chromatin methylation status in CSCs [64, 70, 71, 
76]. The question is how LSD1 selectively targets gene-
specific promoters. One plausible explanation is that 
LSD1 works together with or regulates stem cell factors 
in a subset of CSC types. One candidate factor, SOX2, 
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was reported to cooperate with LSD1 in lung cancer [69], 
HER2-positive breast cancer [77], human ovarian terato-
carcinoma [17], and pluripotent cancer cells, including 
teratocarcinoma, embryonic carcinoma, and seminoma 
CSCs [67]. LSD1 inhibition repressed the expression of 
SOX2 in lung squamous cell carcinomas, resulting in the 
suppression of SOX2-mediated oncogenic potential [69]. 
In human ovarian teratocarcinomas, SOX2 was suscep-
tible to monomethylation-mediated degradation, which 
was reversed by LSD1, and thus LSD1 inhibition caused 
SOX2 destabilization [17]. LSD1 inhibition selectively 
blocked CSC-driven mammosphere formation in SOX2-
driven CSCs [77]. Another stem cell factor, OCT4, was 
also suggested as a stemness-regulating factor working 
in concert with LSD1. The LSD1-OCT4 interaction in 
CSCs was suggested to maintain enhancers suscepti-
ble to reactivation, leading to the abnormal expression 
of pluripotency-related genes [78]. In LGR5-positive 
hepatocellular carcinoma, LGR5 and LSD1 appeared to 
enhance each other’s expression, maintaining the stem 
cell characteristics of carcinoma cells [79]. A key feature 
of neuroblastoma is the impaired neuronal differentiation 
in parallel to the high expression of myelin transcription 
factor 1 (MYT1). Knockdown of MYT1 induced neuro-
differentiation in neuroblastoma cells [80]. Pharmaco-
logical inhibition of MYT1 interaction partner LSD1 had 
similar effects. Therefore, the roles of LSD1 in CSCs need 
to be considered together with those of its interaction 
partners, which are most likely lineage- or cancer type-
specific transcriptional regulators.
LSD1 in anti‑tumor immunity
The immune surveillance system of the human body 
continuously identifies and clears tumor cells through a 
multi-step process. In brief, these steps include the rec-
ognition of tumor-associated antigens by dendritic cells 
(DCs), antigen presentation via major histocompatibil-
ity complexes on the DC surface, the migration of DCs 
to lymphoid organs, DC-T cell contact resulting in T cell 
activation, relocation of activated T cells to peripheral 
tumor sites, and finally, the recognition and cytotoxic T 
cell-mediated destruction of cancer cells [81]. In addi-
tion, tumor antigen-specific B cells proliferate, differenti-
ate, and produce antibodies to help with the destruction 
of cancer cells [81]. However, cancer cells employ various 
mechanisms to perturb and escape from immune surveil-
lance, including immune editing [82]. Therefore, various 
approaches for overcoming the immune escape of cancer 
cells are being actively investigated.
Tumor immunotherapy is a major antitumor treat-
ment approach that has recently emerged into the clinical 
spotlight. It was not long ago that LSD1 inhibitors were 
also shown to be effective in antitumor immunotherapy 
(Fig.  2). Based on the fact that targeting epigenetic 
regulators can boost the antitumor immune response, 
researchers screened compounds targeting chromatin 
factors that upregulate the expression of endogenous ret-
roviral element (ERV)—as well as type I interferon (IFN)-
responsive genes, and identified GSK-LSD1 as a hit [16]. 
Further analysis revealed that LSD1 inhibition caused 
ERV expression in parallel to H3K4me2 upregulation at 
various ERV regions, resulting in the downregulation of 
RNA-induced silencing complex (RISC), which otherwise 
clears double-stranded ERV transcripts. These two phe-
nomena in turn enhanced the cellular response to dsRNA 
by activating type I IFN signaling. In addition, LSD1 
depletion or inhibition enhanced tumor immunogenic-
ity, resulting in increased T cell infiltration of tumors. 
Furthermore, LSD1 inhibition sensitized PD-(L)1-resist-
ant tumor cells to checkpoint blockade [16]. This was 
the first report to highlight the potential application of 
LSD1 inhibition in cancer immunotherapy, especially 
for the treatment of tumors that are poorly immuno-
genic and resistant to PD-(L)1 blockade. In agreement 
with this observation, various researchers reported the 
pro-immunogenic effects of LSD1 inhibition in tumors, 
which lead enhanced immune checkpoint blockade effi-
cacy. LSD1 inhibition in triple-negative breast cancer 
(TNBC) increased the expression of CD8+ T cell-attract-
ing chemokines and PD-L1 in parallel to upregulated 
H3K4me2 marks at the respective gene promoter regions, 
resulting in enhanced CD8+ T cell infiltration at tumor 
sites [83]. Further, combination treatment with LSD1 
inhibitor and an anti-PD-1 antibody in TNBC xenograft 
mice amplified PD-1 blockade efficacy [83]. Enhanced 
antitumor immune responses, including T cell infiltra-
tion, after LSD1 inhibition have also been reported in 
SWI/SNF-mutated ovarian cancers as well as in a 4T1 
melanoma mouse model [84, 85]. Interestingly, LSD1 
deficiency of CD8+ T cells in a murine melanoma model 
resulted in lower tumor growth, higher PD-1 levels in the 
tumor-infiltrating population, and no significant differ-
ence in overall health compared to wild-type mice [86]. 
CoREST complex inhibitor corin, which is derived from 
a class I HDAC inhibitor and an LSD1 inhibitor [87], 
induced the expression of proinflammatory cytokine 
genes in Tregs, resulting in increased CD8+ T cell tumor 
infiltration and reduced tumor burden [88]. Therefore, 
LSD1 inhibition seems to exert anti-tumor effects on 
both tumor and immune cells. Further, it is of interest to 
observe whether a single LSD1 inhibitor can exert similar 
effects on Treg cells as the dual CoREST inhibitor corin.
In addition to modulating tumor immunogenicity and 
PD-(L)1 blockade, LSD1 inhibition potentiates antitu-
mor immunity by activating innate immune cells, includ-
ing macrophages and natural killer cells. In a xenograft 
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model of MDA-MB-231 breast cancer in BALB/c nude 
mice, LSD1 inhibition via phenelzine resulted in 
increased infiltration of anti-tumor M1 macrophages in 
the tumor microenvironment [51]. Further analysis of 
the effect of LSD1 inhibitors on macrophage polarization 
programs revealed that phenelzine could target both FAD 
and CoREST binding domain, while catalytic inhibitor 
GSK2879552 could not switch the macrophage polariza-
tion program toward an anti-tumoral M1-like phenotype 
[89]. In contrast, catalytic inhibitor GSK-LSD1, but not 
scaffold inhibitors, increased natural killer cell-mediated 
tumor regression in a mouse model of pediatric high-
grade glioma [90]. One concern was the cytostatic and 
cytotoxic effects of scaffold-type LSD1 inhibitors on nat-
ural killer cells, which did not affect T cells [90]. This was 
due to the impaired metabolism and glutathione deple-
tion in inhibitor-treated natural killer cells, as glutathione 
supplementation rescued their cytolytic function [91].
Taken together, studies have thoroughly demonstrated 
the beneficial effects of LSD1 inhibition on antitumor 
immunotherapy. In cancer, LSD1 inhibition enhances 
tumor immunogenicity and the secretion of chemokines, 
while reversing resistance to PD-(L)1 blockade. Further, 
LSD1 inhibition increases proinflammatory cytokine 
expression in Treg cells and enhances tumor CD8+ T 
cell infiltration. Antitumor M1-like macrophage polari-
zation and infiltration were also upregulated by LSD1 
inhibition. As LSD1 inhibitors have therapeutic potential 
within immunotherapy, further in-depth research is cru-
cial for determining which type of LSD1 inhibitors (cata-
lytic inhibitor vs. scaffolding inhibitor) is to be used and 
what type of immunotherapy it should be combined with.
Roles of LSD1 in inflammatory diseases
The inflammatory response is the primary defense 
mechanism mediated by the immune system. However, 
in order for the inflammatory response to function effi-
ciently, its induction and termination must be tightly 
regulated, as excessive and prolonged inflammation leads 
to the development of chronic inflammatory diseases [10, 
92, 93]. It has been reported that the epigenetic regula-
tion of gene expression during inflammation is crucial 




T cell attracting chemokines
Resistance to PD-1-PD-L1 blockade 
Proinflammatory cytokines in Treg cells
CD8+ T cell infiltration
T cell
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T cell infiltration ↑
Fig. 2 The effect of LSD1 inhibition on anti-tumor immunity. LSD1 inhibition in cancer cells enhances tumor immunogenicity and secretion of 
chemokines that attract T cells, while reversing the resistance to PD-(L)1 blockade. LSD1 inhibition upregulates pro-inflammatory cytokines in Treg 
cells, promotes the polarization of macrophages into the anti-tumor M1-like macrophages, and enhances the infiltration of these macrophages and 
CD8 + T cells into the tumor
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in inflammatory disease pathogenesis [94–97]. LSD1 
functions as an epigenetic regulator of the inflammatory 
response (Fig. 3) [98–100]. It regulates the expression of 
pro-inflammatory genes through different mechanisms 
depending on the cell type and immune signal. LSD1 
repressed pro-inflammatory cytokines MCP-1 and IL-
6 induced by diabetes in smooth muscle cells (SMCs) 
through the regulation of H3K4me2 [99]. Further, LSD1 
was downregulated in SMCs isolated from a diabetic 
mouse model (db/db), resulting in the increased H3K4 
methylation of NF-κB response elements near the MCP-
1 and IL-6 promoters [99]. In cancer cell lines MDA-
MB231 and HepG2, LSD1 repressed pro-inflammatory 
cytokine genes IL-1α, IL-1β, and IL-6 [98]. LSD1 knock-
down upregulated H3K4me2 at the promoters of IL-1α, 
IL-1β, and IL-6, while H3K9me2 levels decreased. LSD1 
functioned in synergy with HDAC1 to control H3K9/14 
acetylation [98]. In addition, LSD1 was reported to 
act as a negative epigenetic regulator of inflammatory 
responses in hematopoietic stem cells (HSCs) during 
endotoxin shock. LSD1fl/fl:Mx-Cre mice (LSD1−/−), which 
were LSD1-depleted via Poly(I:C), exhibited a dysregu-
lated inflammatory response, leading to hyperinflam-
mation and sudden death because of a cytokine storm. 
When LSD1 was restored in HSCs, these were resistant 
to LPS-induced septic shock. LSD1 directly modulated 
HSC gene expression through H3K4me2 regulation, thus 
preventing excessive inflammatory reactions [100].
LSD1 functions not only as a negative regulator of the 
inflammatory response but may also promote it [15, 101, 
102]. In rheumatoid arthritis (RA), one of the most fre-
quently occurring chronic inflammatory diseases, LSD1 
acts as a positive regulator of CD4+ T cell activation 
[101]. Upregulated LSD1 expression was observed in 
CD4+ T cells within the synovial fluid (SF) of patients 
with active RA. Further, the production of both IFN-γ 
and IL-17 was significantly decreased by LSD1 knock-
down in these cells. In the collagen-induced RA mouse 
model, LSD1 knockdown prevented RA development 
[101]. LSD1 was phosphorylated by PKCα in response to 
LPS stimulation of bone marrow-derived macrophages 
(BMDMs). LSD1 phosphorylation-defective mice 
(Lsd1SA/SA) were highly resistant to LPS-induced inflam-
mation, acute lung injury, and mortality [15]. Further, 
LPS-induced LSD1 phosphorylation was required for 
the prolonged activation of NF-κB target genes. Interest-
ingly, the NF-κB target gene activation associated with 
LPS-induced LSD1 phosphorylation was independent of 
its demethylase activity against H3K4me2 and H3K9me2 
[15]. LPS-induced LSD1 phosphorylation was responsi-
ble for both p65 demethylation and binding, enhancing 
p65 protein stability. Inhibition of PKCα or LSD1 activity 
in mice attenuated sepsis-induced mortality. Therefore, 
phosphorylation by PKCα is critical for LSD1-mediated 
epigenetic regulation of the inflammatory response [15]. 
LSD1 is highly expressed in the renal tissue of hepatitis B 
virus-associated glomerulonephritis (HBV-GN) patients. 
Further, LSD1 promoted HBV-induced pro-inflamma-
tory cytokine release in HK-2 cells, a human renal tubular 
epithelial cell line. LSD1 regulated expression by remov-
ing methylation from H3K9 at the promoter of inflam-
matory response-related gene Tlr4. Tranylcypromine, an 
LSD1 inhibitor, inhibited the TLR4-NF-κB-JNK signaling 
axis and decreased renal inflammation in HBV-infected 
transgenic mice. Taken together, LSD1 functions as a 
novel positive regulator of renal inflammation [102].
SARS-CoV-2, responsible for the current COVID-19 




















Fig. 3 LSD1 functions as a key epigenetic regulator in inflammatory disease. LSD1 controls gene expression in two ways during inflammation. 
LSD1 increases the expression levels of inflammatory response genes by acting as a positive regulator in inflammatory diseases such as rheumatoid 
arthritis (RA), sepsis, hepatitis B virus-associated glomerulonephritis (HBV-GN), and SARS-CoV-2 infection. By contrast, LSD1 functions as a 
negative regulator of the inflammatory response that decreases the expression of cytokine genes in smooth muscle cells (SMCs), cancer cells, and 
hematopoietic stem cells (HSCs)
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severe respiratory syndrome, among which pneumonia 
is the most frequent. SARS-CoV-2-induced pneumonia 
causes a cytokine storm to develop rapidly, leading to 
death. Therefore, the epigenetic suppression of excessive 
inflammation represents a new avenue for the develop-
ment of relevant therapeutics. Epigenetic regulators, 
such as LSD1, may thus represent promising therapeu-
tic targets for the treatment and prevention SARS-CoV-
2-associated pneumonia.
Roles of LSD1 in thermogenesis and adipogenesis
Metabolic conditions, such as obesity and diabetes, are 
associated with the dysregulation of metabolism-associ-
ated gene expression [103, 104]. The best studied function 
of LSD1 in energy metabolism is its role in the positive 
regulation of thermogenic potential in adipocytes. LSD1 
expression was decreased in the white adipose tissue 
(WAT) from ob/ob mice. In normal mice, its expression 
was induced in WAT after cold exposure or β-adrenergic 
stimulation [105]. Further, LSD1 upregulation enhances 
mitochondrial function, inducing the expression of genes 
related to oxidative phosphorylation (OXPHOS) in WAT 
via nuclear respiratory factor 1 (Nrf1) [105]. Transgenic 
mice with increased LSD1 expression exhibited partial 
browning of the WAT with reduced weight gain in high-
fat diet-fed conditions [105]. In addition to the WAT, 
LSD1 contributes to the development, maintenance, and 
state conversion (active thermogenic vs. dormant) of the 
brown adipose tissue (BAT) by controlling the expres-
sion of metabolic target genes [106–108]. BAT-specific 
LSD1 conditional deletion resulted in the morphologi-
cal whitening of the BAT, reduced thermogenic poten-
tial, and increased obesity [106–108]. With respect to 
the mechanism, LSD1 has a dual regulatory role of gene 
expression in the BAT, with upregulation of BAT-specific 
genes and downregulation of WAT-selective genes. The 
upregulation of BAT-specific genes is mediated by the 
interaction of LSD1 with transcription factors such as 
Zfp516, a BAT-enriched and cold-inducible transcrip-
tion factor, and Nrf1 [106, 107]. Zfp516 recruits LSD1 
to the promoter region of BAT-specific genes such as 
UCP1, and LSD1 demethylates H3K9 leading to tran-
scriptional activation [107]. The Nrf1–LSD1 complex 
also targets H3K9 marks and induces BAT-specific gene 
transcription [106]. By contrast, repression of WAT-
selective genes is achieved by the interaction of LSD1 
with PRDM16, a key transcriptional coregulator in adi-
pocytes, and through the LSD1–CoREST complex [106, 
108]. Although LSD1–PRDM16-mediated repression of 
WAT-selective genes correlates with H3K4 demethyla-
tion [108], the LSD1–CoREST complex has a dual regu-
lation function on both H3K4 and K3K9 methylation in 
the same promoter [106]. In addition to the regulation 
of BAT- or WAT-specific gene expression, LSD1 pro-
motes BAT thermogenesis through repressing hydroxys-
teroid 11-β-dehydrogenase isozyme 1 (HSD11B1), a key 
glucocorticoid-activating enzyme, since glucocorticoid 
promotes lipid accumulation [108]. LSD1 binds to the 
promoter region of Hsd11b1 independently of PRDM16 
and demethylates H3K4me2. In a separate study, chemi-
cal inhibition of LSD1 was shown to block BAT differen-
tiation accompanied by the repression of Wnt-β–catenin 
target genes [109]. Consistently, conditional deletion of 
Lsd1 in newborn mice resulted in the inhibition of brown 
adipogenesis [109]. In another context, LSD1 is required 
for the formation and maintenance of thermogenic beige 
adipocytes that turn into white adipocytes with age, and 
PPARα mediates the effects of LSD1 on target genes 
[110]. Overall, it is clear that LSD1 is critical for adipo-
genesis and thermogenic gene regulation, although the 
exact mechanism for the thermogenic gene regulation 
remains to be elucidated further.
Roles of LSD1 in neuronal physiology 
and neurodegenerative diseases
LSD1 is widely expressed in the brain and nervous sys-
tem, regulating gene expression during various processes 
[111–115]. In particular, LSD1 functions as an epige-
netic regulator of neural stem cell proliferation (Fig.  4). 
Its inhibitors pargyline and tranylcypromine lead to 
attenuated neural stem cell proliferation [112]. LSD1 
was recruited to the promoter of TLX target genes for 
transcriptional repression, playing a novel role in regula-
tion via TLX, an essential neural stem cell transcription 












Neuronal Physiology Neurodegenerative Diseases 
LSD1
Fig. 4 Roles of LSD1 in neuronal physiology and neurodegenerative 
diseases. LSD1 regulates gene expression in various neuronal 
physiology processes such as neuronal differentiation, circadian clock, 
learning, and memory. When LSD1 fails to control gene expression, 
neurodegenerative diseases such as Alzheimer’s disease (AD), 
frontotemporal dementia (FTD), and tauopathy occur
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for proteasomal degradation during neural differentia-
tion in vitro as well as in vivo [111]. Further, LSD1 was 
described as critical for neuronal progenitor cell (NPC) 
maintenance during cortical development, controlling 
NPC differentiation by regulating H3K4 methylation of 
ATN1 (encoding Atrophin 1, a protein related to denta-
torubral-pallidoluysian atrophy) [113]. Pharmacological 
inhibition of LSD1 activity increased H3K4 methylation 
at the LSD1 binding site downstream of ATN1, leading 
to ATN1 repression and NPC differentiation [113]. LSD1 
was crucial for the neuronal differentiation of human fetal 
neural stem cells (hfNSCs) [114], being directly recruited 
to the Hairy/enhancer-of-split related with YRPW motif-
like (HEYL) gene promoter and controlling H3K4me2 
demethylation to repress HEYL expression during hfNSC 
neuronal differentiation [114]. Further, LSD1 co-repres-
sor Rcor2 is expressed in the central nervous system 
and plays a key role in the epigenetic regulation of Sonic 
hedgehog (Shh) signaling during cortical development 
[115]. LSD1 and Rcor2 co-occupied the upstream regula-
tory regions of Shh, with the latter recruiting the LSD1 
complex for the removal of H3K4me1 from these genes 
[115].
LSD1 is phosphorylated by PKCα in a circadian man-
ner, and phosphorylated LSD1 interacts with CLOCK-
BMAL1, a master transcriptional regulator, to facilitate 
transcriptional activation [52]. LSD1 phosphorylation-
defective Lsd1SA/SA mice exhibited attenuated expression 
of core clock genes, resulting in altered circadian rhythms 
and impaired phase resetting of the circadian clock [52]. 
Phosphorylated LSD1 was also reported to be involved 
in presynaptic plasticity as well as hippocampal learn-
ing and memory [116]. Lsd1SA/SA mice exhibited signifi-
cant upregulation of presynaptic function-related genes 
[116]. Further, LSD1 counteracted SETD1 activity during 
axonal branching and cortical synaptic dynamics, with 
Setd1 depletion being accompanied by working memory 
deficits [117]. SETD1A, a lysine-methyltransferase, is a 
key schizophrenia susceptibility gene, and cognitive as 
well as circuitry deficits were observed in in Setd1a-defi-
cient mice [117].
As LSD1 acts as a critical regulator of neuronal physiol-
ogy, it has been reported that a lack of normal LSD1 func-
tion contributes to the occurrence of neurodegenerative 
diseases [118, 119]. LSD1 deletion in hippocampal and 
cerebral cortex neurons leads to paralysis, widespread 
hippocampal and cortical neurodegeneration, as well as 
learning and memory defects [118]. Ablation of LSD1 
promoted expression changes in common neurodegen-
eration-associated genes in the degenerating hippocam-
pus. LSD1 was specifically mislocalized to aggregates 
of pathological proteins such as pTau and pTDP-43 in 
Alzheimer’s disease (AD) and frontotemporal dementia 
(FTD) patients [118]. The role of LSD1 in neurodegener-
ation was also explored in mouse models. LSD1 seques-
tration and tau accumulation were observed in the nuclei 
of neurons in a tauopathy mouse model [118]. Further, 
LSD1 deletion in this mouse model affected tau-induced 
gene expression, while LSD1 overexpression rescued the 
neurodegenerative phenotype in the hippocampus of 
tauopathy mice [118]. Therefore, increasing the activity 
and expression of LSD1 may represent a promising thera-
peutic approach for the treatment of AD and FTD [119]. 
Although LSD1 has been reported as related to neuro-
degenerative disease, the detailed molecular mechanism 
of LSD1 remains to be elucidated. Therefore, the study 
of how LSD1 controls neurodegenerative disease-related 
gene expression through epigenetic regulation is a prom-
ising area for future studies.
Concluding remarks
Since LSD1 is an epigenetic regulator involved in a 
variety of physiological processes, it has been associ-
ated with several diseases, including cancer as the most 
representative disease. LSD1 facilitates cancer cell sur-
vival and makes the microenvironment cancer-friendly; 
thus, inhibiting LSD1 function is an attractive strat-
egy to suppress cancer. In  vitro screening has identi-
fied many cancer cell lines that are not responsive to 
LSD1 inhibitors. However, LSD1 plays pleiotropic roles 
in tumor growth, invasion, metastasis, and drug resist-
ance in  vivo through the regulation of hypoxia, EMT, 
cancer stemness, and antitumor immunity. Therefore, 
the coverage of LSD1 inhibitors may be wider than that 
obtained from simple cell line screening. Accordingly, it 
seems necessary to develop a method that can test the 
efficacy of LSD1 inhibitors in a condition that best mim-
ics the in vivo environment rather than a simple cell cul-
ture context. Combination therapy of an LSD1 inhibitor 
with other anti-cancer drugs is also an option worthy of 
consideration.
LSD1 is also involved in the development of vari-
ous pathological conditions or diseases other than 
cancer. LSD1 maintains the balance of the inflamma-
tory response by controlling the expression of vari-
ous cytokine genes. In acute and severe inflammation 
conditions, LSD1 inhibition can restrict the spread of 
inflammation, as demonstrated in a CLP-mediated sep-
sis mouse model [15]. Thus, LSD1 inhibitors may be 
applied to alleviate certain types of inflammatory dis-
eases. Moreover, LSD1 is important for the development, 
maintenance, and thermogenesis in brown and beige adi-
pocytes, and loss of LSD1 function in adipocytes results 
in weight gain in mice. However, in this case, LSD1 inhib-
itors are not suitable for use, as LSD1 function is required 
to induce thermogenesis that is required to burn excess 
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energy and thereby suppress obesity. A new method for 
increasing the expression or activity of LSD1 may be ben-
eficial in this case. Moreover, LSD1 is widely expressed 
in the brain and nervous system, and plays a pivotal role 
in neuronal differentiation, the circadian clock, learn-
ing, and memory. As such, LSD1 plays a critical role in 
neuronal physiology, and when LSD1 dysfunction can 
lead to neurodegenerative diseases such as AD, FTD, and 
tauopathies. However, extensive studies are necessary to 
determine whether LSD1 is suitable as a drug target for 
brain and neurological disorders. Taken together, LSD1 
acts as a key epigenetic regulator of gene expression that 
controls cellular homeostasis and can be a therapeutic 
target in certain diseases. Therefore, gaining an accurate 
understanding of the action mechanism of LSD1 is essen-
tial for overcoming several diseases.
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